AbbVie: Shares Defy Sell-Side Downgrades, And That’s Bullish (Technical Analysis)

view original post

AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.